{
    "nctId": "NCT02280252",
    "briefTitle": "Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response",
    "officialTitle": "Response, Resistance and Metastasis of Locally Advanced Breast Cancer (LABC, Stage 2B-3C) in a Multiethnic Cohort: A Phase II International Multicentric Study of Concurrent Paclitaxel and Radiation",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 69,
    "primaryOutcomeMeasure": "Test the Clinical Effectiveness of Concurrent Paclitaxel and Radiation in a Multiethnic Cohort",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Biopsy proven locally-advanced breast cancer: IIB, IIIA, and IIIB\n* Metastatic breast cancer: limited to the subset of patients with intact breast, locally advanced tumor and involved ipsilateral supraclavicular nodes\n* Measureable disease required\n* Adequate laboratory values:\n\nHgb \\> 10 ANC \\> 1500 Platelets \\> 150,000 Creatinine \\< 1.5 Liver function \\< 3x normal\n\n* Patient \u2265 18 years of age\n* Medically and psychologically able to comply with all study requirements\n* ECOG performance score 0-1\n* CT chest, abdomen, and pelvis performed\n* Mammogram or USG performed\n* Signed informed consent\n\nExclusion Criteria:\n\n* Breast cancer patients with Stage 0, Stage I, or Stage IIA\n* Previous XRT or chemotherapy\n* Presence of distant metastases documented clinically or radiographically with the exception of ipsilateral supraclavicular nodes\n* Pregnancy\n* Inflammatory breast cancer\n* Patients under treatment (or who will have recently been treated) with anti-neoplastic, immunosuppressive or hormonal medications\n* Patients who are found to have a cancer positive for the marker HER-2/neu (applies only to NYU Tisch and Bellevue sites)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}